ENLV Stock Risk & Deep Value Analysis
Enlivex Ltd
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About ENLV Stock
We analyzed Enlivex Ltd using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ENLV through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
ENLV Risk Analysis & Red Flags
What Could Go Wrong
The primary risk is clinical trial failure for Allocetra in either sepsis or knee osteoarthritis. A significant setback in any major trial would severely diminish the company's prospects, deplete its capital, and make future funding extremely difficult, potentially leading to a substantial decline in stock value.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Consistent negative profitability and high cash burn, requiring continuous financing (common for clinical biotech but a risk factor)
- ⚠
Low institutional ownership (though recent increases are positive), indicating less widespread institutional validation
- ⚠
High dependency on successful clinical trial outcomes for a single primary asset (Allocetra)
Upcoming Risk Events
- 📅
Negative or inconclusive clinical trial results for Allocetra in either sepsis or OA
- 📅
Higher-than-expected cash burn leading to significant dilutive financing
- 📅
Failure to secure strategic commercialization partners for key indications
When to Reconsider
- 🚪
Announcements of clinical trial failure (Phase 2b OA or Phase 3 Sepsis)
- 🚪
Significant, unexpected share dilution (e.g., >20% in a single quarter) without substantial clinical advancement
- 🚪
Sustained cash balance below 12 months of projected operating expenses without new financing
Unlock ENLV Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Enlivex Ltd (ENLV) Do?
Market Cap
$193.70M
Sector
Healthcare
Industry
Biotechnology
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.
Visit Enlivex Ltd WebsiteInvestment Thesis
Enlivex represents a compelling high-risk, high-reward investment opportunity due to Allocetra's novel immunotherapeutic mechanism with broad applicability in severe inflammatory conditions like sepsis and knee osteoarthritis, both representing massive unmet medical needs. Recent FDA IND clearance for OA, combined with strategic financing and share repurchase programs, significantly de-risk the pipeline and financial runway, setting the stage for substantial market re-rating upon further clinical success and eventual commercialization.
Is ENLV Stock Undervalued?
Unlock the full AI analysis for ENLV
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
ENLV Price Targets & Strategy
12-Month Target
$8.00
Bull Case
$12.00
Bear Case
$0.50
Valuation Basis
Projected ~10x re-rating within 12 months upon successful Phase 2b OA results and initiation of Phase 3 sepsis trials, targeting a market cap of ~$2B.
Entry Strategy
Consider dollar-cost averaging between $0.70-$0.90, utilizing any dips near the 52-week low ($0.66) as accumulation points, given the recent bullish catalysts.
Exit Strategy
Take initial profits at $4.00 (5x current price), reassess at $8.00 (10x current price) for further potential upside. Implement a stop-loss order if the stock breaks below $0.60 (new 52-week low) for sustained periods.
Portfolio Allocation
5% for aggressive risk tolerance, reflecting the speculative nature but significant upside.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is ENLV Financially Healthy?
Valuation
P/E Ratio
-1.84
PEG Ratio
-0.03
Price/Book
1.07
Profitability
Return on Equity
-62.91%
EPS
$-0.55
Balance Sheet
Current Ratio
6.84
Quick Ratio
6.27
Debt/Equity
0.04
Cash & Equivalents
$30.00M
Other
Beta (Volatility)
1.58
Does ENLV Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat is primarily built on the intellectual property surrounding Allocetra and its unique mechanism of action. As clinical trials progress successfully and new indications are pursued (like OA), the platform's versatility strengthens its competitive position. Regulatory approvals would grant temporary market exclusivity, further cementing the moat.
Moat Erosion Risks
- •Patent expiry or successful challenges to existing patents
- •Development of superior or more cost-effective therapies by competitors
- •Clinical trial failures that diminish the perceived efficacy or safety of Allocetra
ENLV Competitive Moat Analysis
Sign up to see competitive advantages
ENLV Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral. Limited specific data on social media sentiment, but the recent Ondo Finance launch for tokenized shares could generate some retail interest.
Institutional Sentiment
Mixed but showing positive shifts. Analyst consensus is 'Hold' with high median price targets, but Wall Street Zen recently downgraded to Sell. However, recent increases in institutional ownership by Renaissance Technologies and Jane Street are positive signals.
Insider Activity (Form 4)
No specific Form 4 filings reported for ENLV insiders (e.g., no CEO/CFO buys/sells flagged) in the last 90 days. The company did announce a $20M share repurchase program, indicating corporate confidence.
Options Flow
Normal options activity. No specific unusual options flow data was identified in the provided research.
Earnings Intelligence
Next Earnings
Estimated early-to-mid May 2026 (for Q1 2026)
Surprise Probability
Medium
Historical Earnings Pattern
Insufficient historical data in the provided research to establish a clear pattern, but the stock is likely highly sensitive to clinical trial updates and cash runway projections.
Key Metrics to Watch
Competitive Position
Top Competitor
N/A (no direct peers specified in research, operating in specialized immunotherapy for sepsis and OA, requiring a broader comparative analysis within biotech)
Market Share Trend
N/A (pre-commercialization, aiming to capture new market share in sepsis and OA segments if successful)
Valuation vs Peers
Valuation is challenging given pre-revenue status. P/B ratio of 1.07 suggests it is reasonably valued against its book assets for a biotech, potentially at a discount compared to more advanced peers, but its market cap is highly speculative and tied to future drug success.
Competitive Advantages
- •Novel mechanism of action for Allocetra, modulating macrophage activity to rebalance the immune system
- •Proprietary intellectual property and patent protection for Allocetra
- •Expanding pipeline into multiple significant indications (sepsis, osteoarthritis)
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive ENLV Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (expected May-June 2026)
- •Updates on Phase 2b knee osteoarthritis trial patient enrollment and initiation
Medium-Term (6-18 months)
- •Interim data or key milestones from Phase 2b knee osteoarthritis trial (6-12 months)
- •Initiation of Phase 3 sepsis trial or strategic partnership for sepsis commercialization (9-18 months)
Long-Term (18+ months)
- •Full Phase 2b knee osteoarthritis trial results and Phase 3 planning (18-36 months)
- •Phase 3 sepsis trial readouts and regulatory filings (24-48 months)
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ENLV?
- ✓
Positive interim or final data readouts from the Phase 2b knee osteoarthritis trial
- ✓
Announcement of Phase 3 sepsis trial initiation or a major commercialization partnership
- ✓
Cash burn rate vs. available cash and success in securing non-dilutive financing
Bull Case Analysis
See what could go right with Premium
Competing with ENLV
See how Enlivex Ltd compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Enlivex Ltd ENLV | $193.7M | 7.9 | -1.8 | — | — | — | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Enlivex Ltd Makes Money
Enlivex Therapeutics is a clinical-stage biopharmaceutical company focused on developing Allocetra, a novel immunotherapeutic drug designed to reprogram immune cells, specifically macrophages, to rebalance the body's immune response in conditions characterized by severe inflammation. Currently, they do not generate revenue from product sales. Their business model relies on successfully advancing Allocetra through clinical trials (e.g., for sepsis and knee osteoarthritis), obtaining regulatory approvals, and then commercializing the drug either independently or through licensing agreements with larger pharmaceutical partners.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Enlivex Ltd (ENLV)?
As of April 15, 2026, Enlivex Ltd has a DVR Score of 7.9 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Enlivex Ltd?
Enlivex Ltd's market capitalization is approximately $193.7M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Enlivex Ltd use?
ENLV is the ticker symbol for Enlivex Ltd. The company trades on the NCM.
What is the risk level for ENLV stock?
Our analysis rates Enlivex Ltd's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of ENLV?
Enlivex Ltd currently has a price-to-earnings (P/E) ratio of -1.8. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
How often is the ENLV DVR analysis updated?
Our AI-powered analysis of Enlivex Ltd is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 15, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ENLV (Enlivex Ltd) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.